We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Summaries of safety labeling changes approved by FDA—Boxed warnings highlights, January–March 2022.
- Abstract
The article presents summaries of safety labeling changes approved by the U.S. Food and Drug Administration (FDA) from January to March 2022. Revisions to warnings implemented in the three months ended March 2022 include the conversion of the prescribing information on Celexa to Physician Labeling Rule format, the removal of the boxed warning on dutoprol about cardiac ischemia after abrupt discontinuation, and the revised boxed warning on Triumeq.
- Subjects
CITALOPRAM; METOPROLOL; HYDROCHLOROTHIAZIDE; UNITED States. Food &; Drug Administration; LAMIVUDINE; DRUGS; DRUG labeling; DAPAGLIFLOZIN; PHARMACY information services; METFORMIN; ABACAVIR
- Publication
American Journal of Health-System Pharmacy, 2022, Vol 79, Issue 13, p1036
- ISSN
1079-2082
- Publication type
Article
- DOI
10.1093/ajhp/zxac148